astra

British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes.

Xigduo XR is a combination of two anti-hyperglycaemic agents, Farxiga (dapagliflozin), an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, in a once-daily oral tablet.

AstraZeneca global medicines development head Elisabeth Björk said: “The addition of Xigduo XR to our US diabetes portfolio is further evidence of AstraZeneca’s commitment to develop new treatment options for patients with type 2 diabetes.

“The approval of once-daily Xigduo XR provides prescribers and adult patients with another treatment choice, supporting a more personalised approach to disease management.”

“The once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.”

The once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

The drug already obtained approval in Australia to treat adults with type 2 diabetes, along with diet and exercise.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Xigduo (dapagliflozin and metformin hydrochloride), which uses an immediate-release form of metformin, has received European Union approval.

According to Astrazeneca, SGLT2 inhibitors are a new class of medicines that remove glucose from the body through the kidneys.

AstraZeneca develops and markets medicines for cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.


Image: AstraZeneca’s R&D site in Mölndal, Sweden. Photo: courtesy of Erik031.